Interaction of the anticonvulsants, denzimol and nafimidone, with liver cytochrome P450 in the rat

M. Salmona, I. Conti, R. Testa, C. Fracasso, S. Caccia

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The presence of an imidazole moiety in the chemical structure of denzimol and nafimidone suggested that these new anticonvulsants might interfere with cytochrome P450-mediated mixed function monooxygenase activities. We therefore investigated their ability to bind reversibly to rat liver cytochrome P450. Both drugs displayed a type II spectra. The K(s) values of binding were 6.66 and 7.00 mM, respectively, for denzimol and nafimidone. In other in-vitro studies the IC50 of the inhibition caused by denzimol and nafimidone was determined on carbamazepine (CBZ) epoxidation and diazepam C 3-hydroxylatio and N 1-dealkylation. The IC50 values for CBZ epoxidation were 4.46 x 10 -7 and 2.95 x 10 -7 M, respectively, in the presence of denzimol and nafimidone. The IC50 values for diazepam C 3-hydroxylation were 1.44 x 10 -6 and 1.00 x 10 -6 M, respectively, and those for N 1-dealkylation 6.66 x 10 -7 and 5.95 x 10 -7 M. The inhibition of CBZ metabolism was also investigated ex-vivo and in-vitro after single oral doses (15 and/or 60 mg kg -1) of denzimol or nafimidone. Inhibition of CBZ-10,11-epoxidation by the two drugs was time- and dose-dependent. Further studies in-vivo showed that denzimol and nafimidone prolong pentobarbitone sleeping times indicating that both drugs bind to rat liver microsomes and are potent inhibitors in the rat of mixed function monooxygense activities both in-vitro and in-vivo.

Original languageEnglish
Pages (from-to)17-21
Number of pages5
JournalJournal of Pharmacy and Pharmacology
Volume40
Issue number1
Publication statusPublished - 1988

Fingerprint

Anticonvulsants
Cytochrome P-450 Enzyme System
Carbamazepine
Liver
Dealkylation
Inhibitory Concentration 50
Diazepam
Pharmaceutical Preparations
Liver Microsomes
Pentobarbital
Hydroxylation
Mixed Function Oxygenases
nafimidone
denzimol
In Vitro Techniques

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology

Cite this

Interaction of the anticonvulsants, denzimol and nafimidone, with liver cytochrome P450 in the rat. / Salmona, M.; Conti, I.; Testa, R.; Fracasso, C.; Caccia, S.

In: Journal of Pharmacy and Pharmacology, Vol. 40, No. 1, 1988, p. 17-21.

Research output: Contribution to journalArticle

@article{934588641677475c8bd8362424b0f9d6,
title = "Interaction of the anticonvulsants, denzimol and nafimidone, with liver cytochrome P450 in the rat",
abstract = "The presence of an imidazole moiety in the chemical structure of denzimol and nafimidone suggested that these new anticonvulsants might interfere with cytochrome P450-mediated mixed function monooxygenase activities. We therefore investigated their ability to bind reversibly to rat liver cytochrome P450. Both drugs displayed a type II spectra. The K(s) values of binding were 6.66 and 7.00 mM, respectively, for denzimol and nafimidone. In other in-vitro studies the IC50 of the inhibition caused by denzimol and nafimidone was determined on carbamazepine (CBZ) epoxidation and diazepam C 3-hydroxylatio and N 1-dealkylation. The IC50 values for CBZ epoxidation were 4.46 x 10 -7 and 2.95 x 10 -7 M, respectively, in the presence of denzimol and nafimidone. The IC50 values for diazepam C 3-hydroxylation were 1.44 x 10 -6 and 1.00 x 10 -6 M, respectively, and those for N 1-dealkylation 6.66 x 10 -7 and 5.95 x 10 -7 M. The inhibition of CBZ metabolism was also investigated ex-vivo and in-vitro after single oral doses (15 and/or 60 mg kg -1) of denzimol or nafimidone. Inhibition of CBZ-10,11-epoxidation by the two drugs was time- and dose-dependent. Further studies in-vivo showed that denzimol and nafimidone prolong pentobarbitone sleeping times indicating that both drugs bind to rat liver microsomes and are potent inhibitors in the rat of mixed function monooxygense activities both in-vitro and in-vivo.",
author = "M. Salmona and I. Conti and R. Testa and C. Fracasso and S. Caccia",
year = "1988",
language = "English",
volume = "40",
pages = "17--21",
journal = "Journal of Pharmacy and Pharmacology",
issn = "0022-3573",
publisher = "Pharmaceutical Press",
number = "1",

}

TY - JOUR

T1 - Interaction of the anticonvulsants, denzimol and nafimidone, with liver cytochrome P450 in the rat

AU - Salmona, M.

AU - Conti, I.

AU - Testa, R.

AU - Fracasso, C.

AU - Caccia, S.

PY - 1988

Y1 - 1988

N2 - The presence of an imidazole moiety in the chemical structure of denzimol and nafimidone suggested that these new anticonvulsants might interfere with cytochrome P450-mediated mixed function monooxygenase activities. We therefore investigated their ability to bind reversibly to rat liver cytochrome P450. Both drugs displayed a type II spectra. The K(s) values of binding were 6.66 and 7.00 mM, respectively, for denzimol and nafimidone. In other in-vitro studies the IC50 of the inhibition caused by denzimol and nafimidone was determined on carbamazepine (CBZ) epoxidation and diazepam C 3-hydroxylatio and N 1-dealkylation. The IC50 values for CBZ epoxidation were 4.46 x 10 -7 and 2.95 x 10 -7 M, respectively, in the presence of denzimol and nafimidone. The IC50 values for diazepam C 3-hydroxylation were 1.44 x 10 -6 and 1.00 x 10 -6 M, respectively, and those for N 1-dealkylation 6.66 x 10 -7 and 5.95 x 10 -7 M. The inhibition of CBZ metabolism was also investigated ex-vivo and in-vitro after single oral doses (15 and/or 60 mg kg -1) of denzimol or nafimidone. Inhibition of CBZ-10,11-epoxidation by the two drugs was time- and dose-dependent. Further studies in-vivo showed that denzimol and nafimidone prolong pentobarbitone sleeping times indicating that both drugs bind to rat liver microsomes and are potent inhibitors in the rat of mixed function monooxygense activities both in-vitro and in-vivo.

AB - The presence of an imidazole moiety in the chemical structure of denzimol and nafimidone suggested that these new anticonvulsants might interfere with cytochrome P450-mediated mixed function monooxygenase activities. We therefore investigated their ability to bind reversibly to rat liver cytochrome P450. Both drugs displayed a type II spectra. The K(s) values of binding were 6.66 and 7.00 mM, respectively, for denzimol and nafimidone. In other in-vitro studies the IC50 of the inhibition caused by denzimol and nafimidone was determined on carbamazepine (CBZ) epoxidation and diazepam C 3-hydroxylatio and N 1-dealkylation. The IC50 values for CBZ epoxidation were 4.46 x 10 -7 and 2.95 x 10 -7 M, respectively, in the presence of denzimol and nafimidone. The IC50 values for diazepam C 3-hydroxylation were 1.44 x 10 -6 and 1.00 x 10 -6 M, respectively, and those for N 1-dealkylation 6.66 x 10 -7 and 5.95 x 10 -7 M. The inhibition of CBZ metabolism was also investigated ex-vivo and in-vitro after single oral doses (15 and/or 60 mg kg -1) of denzimol or nafimidone. Inhibition of CBZ-10,11-epoxidation by the two drugs was time- and dose-dependent. Further studies in-vivo showed that denzimol and nafimidone prolong pentobarbitone sleeping times indicating that both drugs bind to rat liver microsomes and are potent inhibitors in the rat of mixed function monooxygense activities both in-vitro and in-vivo.

UR - http://www.scopus.com/inward/record.url?scp=0023832271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023832271&partnerID=8YFLogxK

M3 - Article

C2 - 2896768

AN - SCOPUS:0023832271

VL - 40

SP - 17

EP - 21

JO - Journal of Pharmacy and Pharmacology

JF - Journal of Pharmacy and Pharmacology

SN - 0022-3573

IS - 1

ER -